Brian Gastman, Piyush K Agarwal, Adam Berger, Genevieve Boland, Stephen Broderick, Lisa H Butterfield, David Byrd, Peter E Fecci, Robert L Ferris, Yuman Fong, Stephanie L Goff, Matthew M Grabowski, Fumito Ito, Michael Lim, Michael T Lotze, Haider Mahdi, Mokenge Malafa, Carol D Morris, Pranav Murthy, Rogerio I Neves, Adekunle Odunsi, Sara I Pai, Sangeetha Prabhakaran, Steven A Rosenberg, Ragheed Saoud, Jyothi Sethuraman, Joseph Skitzki, Craig L Slingluff, Vernon K Sondak, John B Sunwoo, Simon Turcotte, Cecilia Cs Yeung, Howard L Kaufman
Immunotherapy is now a cornerstone for cancer treatment, and much attention has been placed on the identification of prognostic and predictive biomarkers. The success of biomarker development is dependent on accurate and timely collection of biospecimens and high-quality processing, storage and shipping. Tumors are also increasingly used as source material for the generation of therapeutic T cells. There have been few guidelines or consensus statements on how to optimally collect and manage biospecimens and source material being used for immunotherapy and related research...
November 2020: Journal for Immunotherapy of Cancer